# US 2018/0021436 A1 · ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED Ph EFFECT

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021436 A1
- Document ID: US20180021436A1
- Status: Published application
- Kind: A1
- Application number: 15/722,068
- Filed: 2017-10-02
- Published: 2018-01-25
- Earliest claimed: 2010-04-09
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Faranak Nikfar; Munir Alwan Hussain; Feng Qian
- Web page: https://patentgrep.com/patent/US20180021436A1

## CPC

- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2095: {Tabletting processes}
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B29B 9/12: characterised by structure or composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B29B: PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS

## Abstract

Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.

## Claims

### Claim 1

A compressed tablet comprising atazanavir sulfate and an acidifying agent selected from citric acid, tartaric acid, fumaric acid, ascorbic acid and mixtures thereof.

### Claim 2 (depends on 1)

A compressed tablet according to claim 1 further comprising a precipitation retardant agent.

### Claim 3 (depends on 1)

A compressed tablet according to claim 1 wherein the precipitation retardant agent is selected from the group consisting of polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate, hydroxypropyl cellulose, hydoxypropyl methylcellulose, and hydroxypropylmethylcellulose acetate succinate and mixtures thereof.

### Claim 4 (depends on 1)

A compressed tablet according to claim 1 comprising at least one other agent having anti-HIV activity or the ability to enhance the pharmacokinetics of the atazanavir.

### Claim 5 (depends on 4)

A compressed tablet according to claim 4 wherein the other agent is ritonavir.

### Claim 6 (depends on 4)

A compressed tablet according to claim 4 wherein the other agent is cobicistat.

### Claim 7

A compressed tablet comprising atazanavir sulphate, cobicistat, an acidifying agent and a precipitation retardant agent.

### Claim 8 (depends on 7)

A compressed tablet according to claim 7 wherein the acidifying agent is selected from citric acid, tartaric acid, fumaric acid, ascorbic acid and mixtures thereof.

### Claim 9 (depends on 8)

A compressed tablet according to claim 8 wherein the acidifying agent is present in an amount of 10-30 w/w %.

### Claim 10 (depends on 8)

A compressed tablet according to claim 8 further comprising a precipitation retardation agent selected from polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate, hydroxypropyl cellulose, hydoxypropyl methylcellulose, and hydroxypropylmethylcellulose acetate succinate and mixtures thereof.

### Claim 11 (depends on 10)

A compressed tablet according to claim 10 wherein the precipitation retardation agent is present in an amount of 1-5 w/w %.

### Claim 12

A compressed tablet comprising atazanavir sulphate, cobicistat, an acidifying agent selected from citric acid, tartaric acid, fumaric acid, ascorbic acid and mixtures thereof and a precipitation retardation agent selected from polyvinylpyrrolidone, polyvinylpyrrolidone-vinyl acetate, hydroxypropyl cellulose, hydoxypropyl methylcellulose, and hydroxypropylmethylcellulose acetate succinate and mixtures thereof, wherein the acidifying agent is present in an amount of 10-30 w/w % and the precipitation retardation agent is present in an amount of 1-5 w/w %.
